

A Guide to The Research Review Process at Holos University Graduate Seminary

Contents

What is the purpose of this guide?

Federal Agency Overview

Federal Regulations that Govern the Protection of Human Subjects

Why is an IRB necessary?

Frequently Used Terminology

Research Category Review

IRB Forms

Conflict of Interest

Review Timelines

Post IRB Approval

Data Management

Appendix A: Sample Forms

Appendix B: Human Subjects Research Training (CITI)

What is the purpose of this guide?

This guide describes the background of the review process at the Institutional Review Board at the National Foundation for Energy

Healing, Hummingbird, or Western IRB. Western IRB is the only IRB on this list that can legally do the review if government funds are being used or a government organization is involved. It also provides answers to the most common questions from the research community when conducting research involving human subjects. If you can't find the answer to your specific question, please contact Dr. Melinda Connor at 520-609-1765 or melinda connor@mindspring.com.

What are the Research Compliance Services (RCS)

RCS is the office that administers and supports four areas of research compliance: Conflict of Interest (COI), Responsible Conduct of Research (RCR), Research Misconduct (RMIS) and the Human Research Protection Program (HRPP). For purposes of this document, we will focus on the HRPP and specifically the Institutional Review Board (IRB) part of the review process. Training in these areas are offered by CITI.

What is an Institutional Review Board (IRB)?

An IRB is defined as an administrative body composed of scientists, nonscientists and community members established to protect the rights and welfare of human or animal research subjects recruited to participate in research activities. The level of review is decided by the level of risk to research subjects, and changes the number of board members needed to review. Every full board review will have at least five participants who will be selected based on their expertise and called on to do a review.

What is the Human Research Protection Program (HRPP)?

The HRPP is the administrative office of the IRB. The IRB reviews all human subjects research. The office focuses on supporting research conducted by faculty, staff and students in accordance with applicable federal regulations.

What federal agencies oversee the protection of human subjects?

The Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) are the primary agencies responsible for the oversight of human subjects research in the United States of America. These agencies are under the direction of the U.S. Department of Health and Human Services (HHS). The Department of Health and Human Services (HHS) is the principal agency for protecting the health of all Americans. It is comprised of the Office of the Secretary and 11 operating divisions. The agencies perform a wide variety of tasks and services. For example: research, public health notices, food and drug safety, grant awards and health insurance management.

For additional information regarding HHS please visit their website at http://www.hhs.gov/.

For additional information regarding the FDA please visit their website at http://www.fda.gov/.

What is the Office for Human Research Protections?

The Office for Human Research Protections (OHRP) provides leadership in the protection of rights, welfare, and wellbeing of

subjects involved in research conducted or supported by HHS.

For additional information regarding the OHRP please visit their website at http://www.hhs.gov/ohrp/.

What set of federal regulations does each federal agency implement and oversee?

The OHRP implements Title 45A – Department of Health and Human Services; Part 46- Protection of Human Subjects. (45 CFR 46)

Does 45 CFR 46 have a specific name?

45 CFR 46 is also referred to as the "Common Rule." It is called the Common Rule because several federal department and agencies have agreed to follow 45 CFR 46 in the protection of human subjects in research as a common regulation.

The FDA follows a separate and distinct set of federal regulations. Title 21, Chapter 1-Food and Drug Administration, DHHS; Part 50-Protection of Human Subjects. (21CFR 50)

NOTE: Specific state laws may affect research design as well.

What Federal agencies have agreed to follow the Common Rule?

1. Department of Agriculture

- 2. Department of Energy
- 3. National Aeronautics and Space Administration
- 4. Department of Commerce
- 5. National Institute of Standards and Technology
- 6. Consumer Product Safety Commission
- 7. Agency for International Development (USAID)
- 8. Department of Housing and Urban Development
- 9. Department of Justice
- 10. National Institute of Justice
- 11. Department of Defense
- 12. Department of Education
- 13. Department of Veteran Affairs
- 14. Environmental Protection Agency
- 15. Department of Health and Human Services
- 16. National Science Foundation
- 17. Department of Transportation
- 18. Central Intelligence Agency

Why is a Human Studies Ethics Review (IRB review) necessary?

There are several historical events that led to the formation of an IRB and unfortunately current events also demonstrate the

continued need for an IRB.

1932 - Tuskegee Institute study

US Public Health Service studies the effects of syphilis on African-American men. The men were given periodic examinations but the syphilis was left untreated. The subjects did not consent to participate.

1947 - The Nuremberg Code

The code was developed after Nazi experiments done during WWII. The Code is taken to be the basic principles of protection involving human subjects in research.

1948 - Guatemala Syphilis Experiment

US study which infected soldiers, sex workers and prisoners with syphilis and other STD's. The subjects did not consent to participate.

1964 - Declaration of Helsinki

The declaration was provided to guide physicians in research involving human subjects.

1970 - Tearoom Trade Study

A study of anonymous homosexual encounters done by Laud Humphreys. Subjects were never informed of the study and were later contacted at their homes.

1971 - Stanford Prison Experiment

Philip Zimbardo's study involving students put into the roles of prisoners and guards in a mock prison. After six days the experiment was ended due to the guards becoming abusive.

1974 - National Research Act

The process instituted basic regulations governing the protection of human subjects in research.

1978 - Belmont Report

The Belmont Report identifies three fundamental ethical principles for all human subjects research:

- 1. Respect for Persons
- 2. Beneficence
- 3. Justice

1991 - Federal Common Rule adopted

1997 - Investigator Training Required

All programs and universities which receive federal monies which include human research are required to have investigators trained in Human Subjects Research. (Most states in the US now have this requirement for all human studies research conducted within their state.)

2003 - Havasupai DNA study

Members of the Havasupai tribe had DNA collected for diabetes research. Their DNA was later used in other research resulting in information that was detrimental to the members of the tribe.

Note: All federal monies may be withheld from institutions not in compliance with the "common rule."

Common Terms in Research

Research

Research is a systematic investigation that involves a prospective

plan which incorporates data collection, either quantitative or qualitative. Data analysis is conducted to answer a research question or objective that will either develop a theory or contribute to generalizable knowledge. This knowledge may be applied to populations outside of the specific study population and/or inform policy.

Human Subject

A human subject or a respondent is a living individual that provides data to an investigator through intervention, interaction and/or identifiable private information.

Project

The project would be considered to include all steps that the investigator would undertake to go from theory to publication, or the long-term process. This is commonly confused with the term protocol.

Protocol

The protocol would include logistical procedures, documents, scripts, and templates that will be reviewed by the IRB and subsequently followed by the investigator to conduct the project.

De-identified

The term de-identified indicates that the data does not contain information that would link a participant's identity with the data collected including the ID code. This includes situations where the master list still exists.

Are there different categories in which the IRB can review a project?

Yes, the IRB will review human subjects research within three

different categories:

1) Exempt: No risk

2) Expedited: No greater than minimal risk.

Minimal risk is defined as the probability and magnitude of harm or discomfort anticipated in the research and is not greater than those risks ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

3) Full Board: Greater than minimal risk or does not qualify for an Exempt or Expedited category.

NOTE: Theses and dissertations are not considered class projects. They must be reviewed by the IRB.

What is Exempt Research?

1) Research conducted in established or commonly accepted

education settings involving normal educational practices.

2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures or observation of public behavior to obtain non-sensitive data.

NOTE: Exemption #2 does not apply if:

- The participant can be identified AND it would cause them harm to be identified.
- The research involves surveys, interviews or participant observation with children or other protected populations.
- The research involves observation of sensitive aspects of a participant's behavior.
- 3) Research involving elected or appointed officials and all identifying information remains confidential for the life of the data, which is shredded after 7 years.
- 4) Research involving the collection or study of EXISTING public and/or unidentifiable materials.

NOTE: ALL data to be included within a secondary data analysis protocol must exist at the time in which the research starts. If data will be added through a future primary data collection process, the protocol cannot be reviewed at an Exempt Research review level.

- 5) Research involving the study of public benefit or service programs.
- 6) Research involving a taste and/or food quality or consumer acceptance study.

What is Expedited Research?

Expedited Research involves no more than a minimal risk level.

- 1) Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture.
- 2) Prospective collection of biological specimens for research purposes by noninvasive means.
- 3) Collection of data through noninvasive procedures routinely employed in clinical practice, excluding procedures involving x-rays or microwaves.
- 4) Research involving materials (data, documents, records or specimens) that have been collected or will be collected solely for non-research purposes (such as medical treatment or diagnosis.)
- 5) Collection of data from voice, video, digital or image recordings made for research purposes.
- 6) Research on individual or group characteristics or behavior OR research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation or quality

assurance methodologies.

What is a Full Board Review?

A Full Board Review involves research with greater than minimal risk and may include vulnerable populations.

IRB Forms - What do you have to submit for a review?

Different review boards use different forms. You will have to

use the forms required by the review board you will be using. But the basic information which they will need remains the same. In the appendix A of this booklet are the following sample forms:

- 1) The Project Review Template
- 2) Subject Consent Form
- 3) HIPAA
- 4) Conflict of Interest Form
- 5) Change Request
- 6) Adverse Event Form (Must be submitted within 48 hours of the event and no further research may be conducted until the event has been reviewed.)
- 7) Continuing Review Form

Note: No study subjects may be recruited until you have received your signed approval letter and signed stamped consent.

At Holos you may select from several different Human Subject Review boards. At this time we suggest that you consider the following groups:

Western IRB - http://wirb.com/Pages/default.aspx

National Foundation for Energy Healing – Contact Dr. Connor

Hummingbird - http://hummingbirdirb.com/

If you would like to use an alternate IRB please dialogue with your committee chair.

Most studies will submit the proposal that has been developed in prelims, the project review template and the subject consent form by email to melinda_connor@mindspring.com. If applicable, the HIPAA and the Conflict of Interest form may also be submitted. (Please check with your advisor.) Please have the subject consent form (and HIPAA if applicable) reviewed by an attorney in the state where you will be conducting your research so that you are sure it meets local state requirements.

What is a conflict of interest and why is reporting a requirement?

A conflict of interest is any situation that may have a real or perceived influence on the research results. The IRB requirement will specifically ask about any financial interest or conflict of commitment that you may have that is specific to the IRB project under review.

Are their other forms which I must submit as part of the review process?

Yes.

All studies must include the following:

1) A copy of the CITI Training completion certificate of each member of the study team. This includes anyone who will have

contact with your research subjects and anyone who has access, contact or analyzes any of the study data even if that data is blinded. This can include: data entry, statistician, co-investigators, greeters, office personnel. Instructions on how to access CITI training are in Appendix B.

- 2) Common documents used in the study:
 - 1. Advertisements
 - 2. Fliers
 - 3. Handouts
 - 4. Bulletin Postings
 - 5. Reminders
 - 6. Email Messages
 - 7. Phone Scripts
 - 8. Invitations
 - 9. Postcards
 - 10. Surveys
 - 11. Questionnaires
 - 12. Images
 - 13. Introductions
 - 14. Recruitment Scripts
 - 15. Assessments
 - 16. Standardized Assessments
 - 17. Grant Funding Applications or letters of receipt
 - 18. Site Permission Letters
 - 19. Informed Consent
 - 20. HIPAA
 - 21. Chart requests
 - 22. Study Insurance approval

What does a study review cost?

The cost of study reviews vary with the complexity and the organization you are using to do the review. They can range from \$0-\$4500+ depending on study requirements. It is useful to generally plan to spend \$1000-\$2000 on your study review. If you are involved in some organization that requires a federally approved IRB then plan on \$4500+.

Holos University has arranged for a small number of grants from the Alumni Association to help defray the cost of IRB review. Please contact the Dean of Students for more information. If you are interested in pursuing a grant for your research please contact Dr. Melinda Connor.

How long does it take to receive an IRB approval?

Approval time varies depending on the board you are using, the number of projects which they have under review, the quality of the project submitted and the amount and content of the revisions that were requested.

- Exempt Review typically requires a minimum of two weeks for a determination and can run as long as 9 months.
- Expedited Review typically requires a minimum of three weeks with review conducted by three member of the IRB.
- Full Board Review typically requires at a minimum of one month for review by the convened IRB.

When a form is returned with a "revisions requested" status, how much time is allowed to complete the required revisions?

Most boards allow 14 days for re-submission of revisions that are requested. However, the sooner revisions are submitted, the sooner IRB approval will be obtained.

What will I receive from the IRB that shows I have permission to go forward?

You will receive a signed, dated letter with a study number which states that you are approved to proceed. You will also receive a signed stamped consent which must be used for your consent process. Be aware that each subject must sign two copies of the consent form. One copy they will keep for their records and one copy is for your study records. NFFEH offers free one hour training class via skype or zoom with the IRB on how to properly consent research subjects when your receive your study approval. Please feel free to take advantage of this offer.

What kind of data management requirements will I have to meet for my study?

All study data must be kept for 7 years and must be kept in locked file cabinets. Study data which is transported to and from a study site must be kept in a locked brief case and during transport must be kept in the trunk of the car or a fire proof safe.

Demographic data and subject number assignment lists must be kept in a separate file drawer from all other study data.

If the data is kept on a computer, the computer must be start-up password protected and all study documents must be individually password protected. Again, the study data must be kept for 7 years and then shreaded.

(Please note: Research data may not be kept on the "cloud" in any form nor may it be backed-up onto a cloud platform as neither are private or protected environments. Further, if investigators are using computers which have Windows 10 installed as the operating system the release must have been installed as a custom installation with all 24 privacy flags turned on.)

Principal investigators are encouraged to back up all study data appropriately and maintain a back up copy in a fire-proof environment. Health and Human Services of the state or federal government may at any time seek to review human studies research data and cannot be refused. All investigators should keep this in mind when organizing their study data.

Have great success!

We at Holos wish you great success as you move forward in your career and doing your research. If you have any questions or problems please contact your committee chair, the Dean of your department or the Vice President in charge of research.

Appendix A: Sample Study Forms
Project Review Form

Project Title:					
Title on consenting documents (if different from project title):					
IDENTIFICATION OF PI(s)					
Principal Investigator(s):	Degree(s):	Status/rank:	Department:	College:	
Faculty Advisor (if PI is a student):					
PI CONTACT INFORMAT	TION				
Contact phone:		_ Fax: _ _			
Email:		_ Campus Mailing _ address if _ applicable (PO Box):	3		

Advisor contact information	N	
Contact phone:	Fax:	
Email: -	Campus Mailing address:	
PROJECT START DATE:	PROJECT END DATE:	
SUPPORT Is this research project s extramural funding?	upported by intra- orYes	No
If "yes", sponsoring agency/ies:		
Amount of funding:		

NOTE: The full grant application must be submitted if the research described in your PRF is in conjunction with a grant proposal.

Verification of Human Subjects Training

All individuals conducting research involving human subjects (with or without financial support of any sponsoring organization or agency) must complete Human Subjects training. Those individuals include principal investigators, co-investigators and all other individuals involved in the conduct of research. Students and their advisors must meet the same standard as faculty and staff.

Please list all individuals involved in the above-cited research study

Name	Researc h Role (PI, Co-PI, Collaborato r, Sub-I, Data Manager, Research Assistant, etc.)	Will this person be involved in the consentin g process?	Training Title Indicate type of training: Biomed, SBS, and/or CITI-Biomed, CITI-SBS (see definitions below)**	Completion Date(s) for each Human Subjects training listed (mm/dd/yy)
		YES NO		

YES NO	
YES NO	
YES NO	
YES NO	
YES NO	

^{*}Consent forms are to be signed and dated by the subject (or their legal representative) and by the Principal Investigator or Co-Principal Investigator (no other study personnel may sign as Investigator without prior approval of the IRB). Other study personnel involved in the consenting process may sign as Presenter, but not as Investigator.

**CITI-Biomed,

CITI-SBS: Collaborative Institutional Training Initiative – www.citiprogram.org

Author: University of Miami

Biomed: Biomedical and Social/Behavioral Science Researchers

Text: <u>Protecting Study Volunteers In Research</u>
Authors: <u>Cynthia McGuire Dunn/Gary. L. Chadwick</u>

SBS: Social/Behavioral Science Researchers only

Text: <u>Planning Ethically Responsible Research</u>

Author: Joan E. Sieber

ASSURANCES

If appropriate, after review by the Departmental Review Committee, please forward their opinions and comments along with the signatures on the Project Review Form to the Human Subjects Protection Program, National Foundation for Energy Healing 31907 South Davis Ranch Rd. Marana, AZ 85658. Only one copy is required and will be retained for the Human Subjects Protection Program files and eventually microfilmed for a permanent record. Please provide responses to all of the following items.

1. PRINCIPAL INVESTIGATOR

By signing below, I, the Principal Investigator, assure that all other investigators (co-investigators, collaborating

investigators, involved statisticians, consultants, or advisors) are fully aware of, and concur with, the project submission and that all Human Subjects training verification information provided in this form is accurate. I agree that no procedural changes relating to the research will take place without prior review by the IRB.

The following statement refers to concerns regarding Conflict of Interest, such as financial, administrative, or authoritative matters that may influence any aspect of your research for which the IRB Committee should be aware:

Financial Interest Statements:

a) Do ANY of the investigators or research personnel (or relatives) serve as a speaker or
consultant to the sponsor, the manufacturer, or the owner of the product or program being
evaluated?

 \square Yes \square No

b) Do ANY of the investigators or research personnel (or their relatives) have a proprietary interest, derive a direct or indirect benefit, hold equity or receive income annually from the sponsor, manufacturer, or owner of the product or program being evaluated?

□ Yes □ No

c) Do ANY of the investigators or research personnel (or relatives) serve in an administrative or advisory capacity to the sponsor (e.g., Board of Directors with or without compensation)?

□ Yes □ No			
If yes to ANY of the above, attach o	copy of Conflict of Inte	erest and Commitment Di	sclosure Form.
Principal Investigator (Print)	Signature	Date	
2. SUPERVISING OFFICIAL (IF PI	is a student)		
I certify that (1) the resources necessar but are not limited to; staffing and per psychological, social, or medical ser research participation); psychological, protect participants, and resources for p (2) I assume the responsibility for e investigator(s); (3) no procedural clallowed without prior review by the procedures to be used for obtaining and FDA regulations; (5) I certify the goals and techniques stated in the	sonnel (in terms of available social, or medical monoarticipant communications relating to the Human Subjects Corg informed consent coat the investigator(s)	ilability, number, expertise, or social support services intoring, ancillary care, equion (e.g., language translation nce, integrity, and ethical human subjects involved mmittee; (4) I am satisfied omply with the spirit and	and experience); required due to pment needed to a services) conduct of the will be d that the intent of DHHS
I certify that signed consent forms and retained for a period of 6 years		(administrative ro	oom/building)

Date

Signature

Title

PROJECT ABSTRACT

In the space below, provide an abstract of the project in 400 words or less. Include information about (a) the background and rationale for the study; (b) the purpose and objectives; (c) methods to be employed and (d) significance of the study.

1. POPULATION

- a. Number of persons to be recruited for participation in the study:
- b. Describe the population to be recruited and rationale for their participation (indicate age range, gender, and ethnicity). Note any special efforts to encourage the recruitment of women and/or representatives from racial or ethnic minority groups.
- c. Does your study involve vulnerable populations such as children, pregnant women, prisoners, or cognitively impaired subjects, or populations at risk of transitioning into one of these vulnerable categories during the course of your study (e.g. a longitudinal study involving illegal drug users who are at risk of becoming incarcerated while in the study)?
- d. What are the inclusion and exclusion criteria for study participation?
- RECRUITMENT AND CONSENT PROCEDURES. For each response in this section, note
 whether the activity will be done orally, in writing, or both. List points to be covered in
 an oral or written presentation here. Place consent documents in Appendix A. Include
 copies of any visual material (advertisements, flyers, web announcements, etc.) in
 Appendix B for approval.
- a. Describe how potential participants will be identified and how you will respect and protect their privacy during recruitment.
- b. Describe how you will contact individuals who may become participants in the study (e.g., web site, email, flyers, phone calls, advertisements).
- c. Describe how the project will be explained to individuals when you recruit them for participation (include the text of advertisements, phone solicitations, etc). Include any pre-screening questions or surveys that may be used.

- d. Describe how informed consent will be obtained. If the participants are minors or of another vulnerable population, explain how assent or legal consent will be secured. Include if appropriate, the steps you will take to allow sufficient time for the participant to think about their participation or time to review the consent form with family or friends, prior to consenting. If an informed consent document is inappropriate for your project, explain why and how you will ensure informed consent.
- e. How will you make it clear to the recruits that their participation is voluntary and that they may withdraw at any time?
- f. Describe the additional safeguards you will use to protect participants from coercion or undue influence, during recruitment and throughout the study (e.g. if the participants are students and the investigator is their teacher).

3. METHODOLOGY AND DATA COLLECTION PROCEDURES

- a. Is your project evaluating an active intervention or treatment procedure (to determine whether an intervention/treatment is effective for the people undergoing it)?
 - Yes No If yes, in lay terms provide a summary of the intervention and/or treatment methods and procedures to be employed
- b. What type of data collection and recording will be employed? Check all that apply and provide an explanation. (If Administrative Records are to be used, include a letter of authorization from the appropriate agencies in Appendix C. Include samples of all data collection instruments in Appendix D.)

╙ _	Questionnaires/Surveys	Interviews/Focus Groups
	Observations	Records Review (medical)
		educational, etc.)
<u> </u>	Videotaping	Audiotaping
_ _	Photography	Other (define):
	Participant observation	

- c. In lay terms, provide a description of the research methods (including deception) and procedures for data collection that will be employed.
- d. Describe the procedures you will use to respect and protect the research participant's privacy (physically, behaviorally, or intellectually) during the data collection process (e.g. during the interview the participant will meet with the researcher in a location away from his/her place of employment).
- e. Describe when appropriate, how the research plan makes adequate provision for monitoring of data when participant safety is a concern, or identification of or support for distressed participants to ensure their safety (e.g. Participants who may self-identify for depression will be provided with referral information so they may seek professional help.)
- f. Where will the project be conducted? If study is to be conducted anywhere outside your department (e.g., in another department, at an off-campus agency or organizational location), include a letter of authorization in Appendix C, or state when it will be provided to the Human Subjects Protection Office. If your project takes place off-campus but site authorization is inappropriate, explain why.
- g. Are you the lead investigator of a multicenter study?
 - i. If yes, describe the plan for communicating the following information (relevant to the protection of research participants) among the sites involved in this study:
 - Unexpected problems
 - Protocol modifications
 - Interim results

4. CONFIDENTIALITY OF PERSONAL IDENTIFYING INFORMATION

- a. What procedures will be followed to ensure that the information obtained about them will be stored in a secure manner? (Specify how the confidentiality of data will be maintained throughout the research.)
- b. What are the plans for retention and/or destruction of linkages between study data and personal identifying information? (Specify when and how personal

identifying information will be destroyed.)

- c. If these linkages will not be destroyed, explain how you will maintain confidentiality of the personally identifying information.
- d. In the event that personally identifying information will not be kept confidential, explain why not and explain how you will ensure that the subjects are consenting to your sharing this information.
- e. Will a Certificate of Confidentiality (through DHHS or another Federal agency) be utilized?

5. BENEFITS, COSTS, COMPENSATION & RISKS

a. Benefits: i. What are the potential benefits directly to the participants, if any?

Benefits: ii. What are the potential broader benefits of the study?

- b. Costs: What are the costs to the participants (monetary, time, etc)?
- c. Compensation: Will monetary or other compensations be offered to the subjects? (If so, identify the amount of compensation and method of payment.)
- d. Risks: i. What risks to the participants could be encountered through participation in this project (physical, psychological, sociological, financial, economic, etc)?

Risks: ii. Describe the approaches you will take to minimize these risks and/or to minimize their impact.

6. **APPENDICES**

Attach the following appendices to the PRF, in the order specified, labeled as

indicated, and with a table of contents identifying all appendix materials. Use

titles that are consistent with those used in the text of the PRF.

A.1 Subject Informed Consent Form/Parental Informed Consent Form

A.2 Minor Assent Form

В. **Recruitment Materials**

C. Site Authorization Letter (for study conduct and/or access to

administrative records)

D. **Data Collection Instruments**

E. **Grant Applications**

F. HIPAA documentation.

Revised: 04/10

RESEARCH PARTICIPANT CONSENT FORM

GUIDELINES FOR SUBJECT'S CONSENT FORM(S)

The written consent form must be in a language easily understood by the subject. Avoid technical terms or explain thoroughly in simple lay language if they must be used. Essentially the form should represent the subject's statement in his/her own words since he/she will sign it. The forms should be titled "Subject's Consent Form" and should contain the basic elements of informed consent. The legality of the subject's

signature is the responsibility of the principal investigator. (The following elements must be separately titled and addressed.)

(This paragraph must be used verbatim following the title - preferably in capital letters.)

I AM BEING ASKED TO READ THE FOLLOWING MATERIAL TO ENSURE THAT I AM INFORMED OF THE NATURE OF THIS RESEARCH STUDY AND OF HOW I WILL PARTICIPATE IN IT, IF I CONSENT TO DO SO. SIGNING THIS FORM WILL INDICATE THAT I HAVE BEEN SO INFORMED AND THAT I GIVE MY CONSENT. FEDERAL REGULATIONS REQUIRE WRITTEN INFORMED CONSENT PRIOR TO PARTICIPATION IN THIS RESEARCH STUDY SO THAT I CAN KNOW THE NATURE AND RISKS OF MY PARTICIPATION AND CAN DECIDE TO PARTICIPATE OR NOT PARTICIPATE IN A FREE AND INFORMED MANNER.

PURPOSE

I am being invited to participate voluntarily in the above-titled research project. The purpose of this project is (state specifically why the study is being proposed).

SELECTION CRITERIA

I am being invited to participate because (give brief description of inclusion and exclusion criteria). Approximately (insert number) subjects will be enrolled in this study.

STANDARD TREATMENT(S)

Include a brief description of standard treatment(s) available as an option if he/she does not wish to participate in this study.

PROCEDURE(S)

If I agree to participate, I will be asked to consent to the following: (include each procedure [in simple lay terms], state time requirements, and list measurements [i.e., inches, etc., blood to be drawn {teaspoons, tablespoons, ounces}], skin biopsy [size, location]). If the study is blind or double-blind, describe the groups clearly. Subjects must be aware they will be assigned (randomized) to a group by chance, "like the

flip of a coin". Listing procedures in the consent form is adequate only if supplemented with an oral description to the subject with more detailed information to comply with the requirement for "fully informed consent".

RISKS

List the most common serious risks Project Approval Form (or the questionnaire/survey Project Approval Form). State in lay terms and include % incidence, if known, and precautionary measures to be taken. The possibility of psychological and/or social risks involved in study participation must also be stated clearly. If the study is placebo-controlled, subjects must be informed that there is a possibility that they will receive no treatment, and the consequences of this (or withholding previous treatment regimen) should be explained.

BENEFITS

A benefit is a valued or desired outcome. If there are no benefits, so state. Benefits associated with participation in research can be classified as those that accrue to the subject directly such as improvement in health status, acquisition of useful information from examination or testing, and those that accrue to society (e.g., societally important and generalizable information). Financial or other forms of compensation should not be considered a benefit to be derived from

the research goals and procedures and as such, should be listed under Participation Costs and Subject Compensation.

CONFIDENTIALITY

Explain how confidentiality will be maintained. List people by category and/or by name who will have access to the data.

PARTICIPATION COSTS AND SUBJECT COMPENSATION

It is considered unethical (in most cases) to have a research subject pay for experimental drugs and the laboratory costs involved. Please state clearly the costs the subject and/or third party payors will assume (including hospital stay). If there are no costs, so state. If subjects will be paid, state the amount (add proration for partial completion of the study). This will usually be commensurate with time lost and expenses, and must not be in amounts excessive enough to represent potential financial coercion. Specify any compensation provided to the subjects (e.g., gift certificates, training sessions, etc.).

CONTACTS [for projects involving no known risk(s) to subjects, include the following sent	:ences]
I can obtain further information from the principal investigator (name of the principal Investigator plus his/her degree, M.D., Ph.D., Pharm.D., Ph.D. Candidate, etc.) as a research subject, I may call the Foundative at (520) 609-1765.	•
LIABILITY (for projects involving greater than minimal risk - use this paragraph verbatim)	

Side effects or harm are possible in any research program despite the use of high standards of care and could occur through no fault of mine or the investigator involved. Known side effects have been described in this consent form. However, unforeseeable harm also may occur and require care. I do not give up any of my legal rights by signing this form. In the event that I require or am billed for medical care that I feel

has been caused by the research, I should contact the principal investigator				
(na	ne of Principal Investigator plus his/her degree, M.D.,			
Ph.D., Pharm.D., Ph.D. Candidate, etc	.) at () If I have questions concerning my rights			
as a research subject, I may call the H	uman Subjects Committee office at (520) 609-1765.			

AUTHORIZATION (the following paragraph is to be used verbatim in all consent forms with two exceptions: delete words "or by the sponsor" if unfunded and no sponsor and "or affecting my medical care" if not clinical, medical treatment)

BEFORE GIVING MY CONSENT BY SIGNING THIS FORM, THE METHODS, INCONVENIENCES, RISKS, AND BENEFITS HAVE BEEN EXPLAINED TO ME AND MY QUESTIONS HAVE BEEN ANSWERED. I MAY ASK QUESTIONS AT ANY TIME AND I AM FREE TO WITHDRAW FROM THE PROJECT AT ANY TIME WITHOUT CAUSING BAD FEELINGS OR AFFECTING MY MEDICAL CARE. MY PARTICIPATION IN THIS PROJECT MAY BE ENDED BY THE INVESTIGATOR OR BY THE SPONSOR FOR REASONS THAT WOULD BE EXPLAINED. NEW INFORMATION DEVELOPED DURING THE COURSE OF THIS STUDY WHICH MAY AFFECT

MY WILLINGNESS TO CONTINUE IN THIS RESEARC	H PROJECT WILL BE GIVEN TO ME AS IT
BECOMES AVAILABLE. THIS CONSENT FORM WILL	BE FILED IN AN AREA DESIGNATED BY THE
HUMAN SUBJECTS COMMITTEE WITH ACCESS RES	TRICTED TO THE PRINCIPAL INVESTIGATOR,
OR AUTHORIZED REPRESEN	ITATIVE OF THE
	VE UP ANY OF MY LEGAL RIGHTS BY SIGNING
THIS FORM. A COPY OF THIS SIGNED CONSENT FO	ORM WILL BE GIVEN TO ME.
Subject's Signature	Date
Parent/Legal Guardian (if necessary)	Date
Witness (if necessary)	Date
INVESTIGATOR'S AFFIDAVIT	
I have carefully explained to the subject the natur	
the best of my knowledge the person who is signi	-
nature, demands, benefits, and risks involved in h	-
legally valid. A medical problem or language or ed	ucational barrier has not precluded this
understanding.	
Signature of Investigator	Date

GUIDELINES FOR SUBJECT AUTHORIZATION FORM FOR USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION (PHI) FOR RESEARCH

This form must be in a language easily understood by the subject. Avoid technical terms or explain thoroughly in simple lay language if they must be used. The form should represent the subject's statement in his/her own words since he/she will sign it. The forms should be titled "Authorization Form for Use and Disclosure of Protected Health Information for Research" and contain the elements required for an authorization form as designated by the Office for Civil Rights. The legality of the subject's signature is the responsibility of the principal investigator. (The following elements must be titled and addressed separately.)

(This paragraph must be used verbatim following the project title.)

The United States government has issued a new privacy rule to protect the privacy rights of individuals enrolled in research. The Privacy Rule is designed to protect the confidentiality of an individual's health information. This document hereafter known as an "Authorization for Use and Disclosure of Protected Health Information for Research" describes my rights and explains how my health information will be used and disclosed for this study.

PURPOSE

I am being invited to participate voluntarily in the above-titled research project. The purpose of this project is (state specifically why the study is being proposed). (A description that relates to the need for medical information is acceptable.)

USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION

Provide a description of information to be used or disclosed and include reason why the information is needed for the study (access should be limited to minimum amount of information necessary to attain study goals). State how long the information will be linked to the subject's identifying information. The information should be understandable to the individual, not merely a list of elements understandable only to the research team. Terms such as lab tests, clinic visit information, X-ray reports are appropriate. Avoid other unnecessary medical jargon. This information will be used for (describe how the information will be used.) Indicate who is providing the information (list the person/organization providing the information) to (list the person/organization receiving the information). I have the right to access my PHI that may be created during this study as it relates to my treatment or payment. My access to this information will become available only after the study analyses are complete. (IF the research subject's access rights are to be suspended while the study is in progress, the authorization form must include an agreement to this denial of access and that the right to access PHI will be reinstated at the conclusion of the study.)

CONTACTS (Include the following sentences)					
I can obtain further information from the principal investig	gator (name of				
Principal Investigator plus his/her degree, M.D., Ph.D., Pharm.D., Ph.D. Candidate, etc) at					
) If I have questions concerning my rights as a re	esearch subject, I may call the Human				
Subjects Protection Program office at 520-609-1765.					
AUTHORIZATION					
I hereby authorize the use or disclosure of my individually withdraw this authorization at any time by notifying the address for the Principal Investigator is (insert address here any information previously disclosed cannot be withdrawn information about me is disclosed in accordance with organization that receives this may redisclose it and my information by Federal Privacy Regulations. I may refuse to sign this assign this form, I cannot participate in the research study present or future medical care and will not cause any lost entitled. This authorization will expire on the date the include actual date of expiration, occurrence of a participation will have no expiration date].) I will be give form.	Principal Investigator in writing. The re.) If I do withdraw my authorization, an and may continue to be used. Once this authorization, the individual or formation may no longer be protected authorization form. If I choose not to provide the second second to the second second to the second the se				
Subject's Signature	Date				
Printed Name of Subject					
Signature of Subject's Legal Representative (if necessary)	Date				
Printed Name of Subject's Legal Representative	Relationship to the Subject				

Use to request a modification to previously approved research				
IRB Project No.:				
Protocol Name:				
Investigator:				
Investigator's Contact Information:				
Alternate Contact:				
Alternate Contact's Information:				
	Approvals Require	ed Prior to Modifying Research		
Does this modifica	tion involve?	Prior to initiating the research approval is required by:	Have you obtained approval?	
A change in use, type, or frequency of radiation, laser, or MRI	☐ No ☐ Yes	Radiation Safety Committee	☐ No ☐ Yes	
The use of any biohazards	☐ No ☐ Yes	Biosafety Committee	□ No □ Yes	
A change to any reportable interests	☐ No ☐ Yes	Institutional Review Committee	☐ No ☐ Yes	
Privacy issues	☐ No ☐ Yes	Privacy Board	☐ No ☐ Yes	
	Summarize the mo	dification or attach a summary:		

Update the Investigator Protocol if affected by the modifications.

Provide 1 copy of the following documents if affected by the modification:

- FORM: Application for Human Research.
- Investigator Protocol
- Research tools
- Data collection instruments (questionnaires, etc.; do not submit case report forms).
- All written materials to be provided to or meant to be seen or heard by subjects, including:
 - o Evaluation instruments and surveys
 - Advertisements (printed, audio, and video)
 - o Recruitment materials and scripts
 - Consent documents
- If consent will not be documented in writing, a script of information to be provided orally to subjects

Provide one copy of the following documents when they have been modified:

- Grant application
- Current product information for each investigational device
- Foreign language version of any written material to be provided to or meant to be seen or heard by subjects.

Investigator Acknowledgement	
I agree to conduct this Human Research in accordance with applicable regulations a Foundation for Energy Healing policies and processes.	nd the National
Investigator signature	Date

Use for both continuing review and as a final report to close a study. If modifications are being requested, submit a separate request for a modification.										
IRB Project No.:										
Expiration Date:										
Protocol Name:										
Investigator:										
Investigator's Contact										
Information:										
Alternate Contact:										
Alternate C	Contact's rmation:									
IIIIO	mation.									
			E	nrollmen	t Status	S				
Number of subje	cts enrolle	ed:								
	Since ac	ince activation		Since last approval		9	Female	Other, Unknown		nknown
Total locally:										
Total all sites:										
Number of subje	cts enrolle	ed locally	since activ	ation of t	he stud	ly:				
Caucasian	Black	ck Hispanic		Asian Pacific Islander		r	American Indian/ Alaska Native		Other, Unknown	
Total number of	subjects c	onsidere	d members	s of vulne	rable p	орι	ılations:			
Children	Prisone	ers	Fetuses	Pregna	Pregnant		Students	Cognitively Impaired		Other
			Financ	ial Interes	t Decla	rat	ion			

The Principal Investigator hereby affirms that ALL appropriate project personnel have submitted an ROI to the Conflict of Interest Office and <i>no</i> outside interests related to this project have been disclosed by any individual.
The Principal Investigator hereby affirms that ALL appropriate project personnel have submitted an ROI to the Conflict of Interest Office and outside interests <i>have</i> been disclosed by one or more individuals that must be reviewed by the Institutional Review Committee (IRC) to determine whether a conflict exists related to this project.

Yes*	No	The following questions refer to all sites involved in the research:	
		Since the last IRB review, have subjects experienced any harms (expected or unexpected)?	
		Since the last IRB review, have subjects experienced any benefits?	
		Since the last IRB review, have there been any unanticipated problems involving risks to subjects or others since the last IRB review?	
		Since the last IRB review, have any subjects withdrawn from the research?	
		Since the last IRB review, have any subjects or others complained about the research?	
		Since the last IRB review, have there been any publications in the literature relevant to the risks or potential benefits research?	
		Since the last IRB review, have there been any interim findings?	
		Since the last IRB review, have there been any multi-center trial reports?	
		Since the last IRB review, have there been any data safety monitoring board reports?	
		Since the last IRB review, has there been any other relevant information regarding this research, especially information about risks associated with the research?	
		In the opinion of the principal investigator, have the risks or potential benefits of this research changed?	
		Since the last IRB review, have there been any modifications to the research?	
		Are there any problems that required prompt reporting that have NOT been submitted as required?	
		Have all serious adverse events and unanticipated adverse events in Veterans Administration (VA) research been reported as required? Check N/A if this is not Veterans Administration (VA) research.	
*Attach a summary explanation or description for each question whose answer is "Yes."			
Current Protocol Status			
Check all that are true or not applicable			
	The re	esearch is permanently closed to enrollment.	

All subjects have completed all research-related interventions.
Collection of private identifiable information is completed.
Analysis of private identifiable information is completed.
If all items are checked, the research may be concluded
Otherwise, the <u>Human Research</u> must undergo continuing review by the IRB.

Provide 1 copy of the consent documents to be used in the next approval period (See Investigator Manual for additional instructions related to these documents). If consent will not be documented in writing, a script of information to be provided orally to subjects. This may be omitted if the research is permanently closed to enrollment.

Investigator Acknowledgement	
I agree to conduct this Human Research in accordance with applicable regulations a Foundation for Energy Healing policies and processes.	nd the National
Investigator signature	Date

National Foundation for Energy Healing

CONFLICT OF INTEREST AND COMMITMENT DISCLOSURE

NAME:
DATE:
DEPARTMENT/ COMPANY:
ADDRESS:
TELEPHONE:
1. If your potential conflict of interest confers a benefit (pecuniary, property, or proprietary), directly or indirectly, on you or a member of your family and the benefit exceeds a remote interest provide a full description of the activities including actual valuation and method of determining stated value.
2. If your responsibilities or commitment to the work (teaching, research, service, or other activities) are or will be affected by the outside interest, please explain. All related activities must be included.
3. If your interest is with a company or other legal entity, provide:
a. Name:
b. Nature of the business activity:
c. Address and Telephone Number:
SIGNATURE:
DATE:

Please feel free to attach additional pages to this form if the space allotted is insufficient to fully describe and to explain the potential conflict of interest.

Appendix B: Human Subjects Research Training How do investigators complete human subjects training?

Holos University uses the Collaborative Institutional Training Initiative (CITI), a web-based program, to provide an educational access to the federally required human subjects training curriculum at www.citiprogram.org.

Who needs to complete CITI training?

All investigators conducting human subjects research are required to complete the proper CITI training course. This includes faculty, staff, students and any unaffiliated collaborators.

What course is required and when?

Most Holos investigators will complete the Research Training Independant Investigator Social Behavioral BASIC course. If you are conducting medical research you will complete the combined BioMedical/Social Behavioral BASIC course. All study team members must complete the training with a grade of 87% or better prior to submitting the IRB review request. Please include a copy of each team members CITI training completion report as an appendix to the project review submission. Both of these courses will be listed under the Research BASIC section.

Are investigators required to take a human subjects training course annually?

No, each course (basic and refresher) is valid for three years.

